FemPulse Enrolls 1st Patient in Feasibility Study for OAB in Women

FemPulse is looking to make an impact in the bioelectronic medicine market with therapy for the personalized treatment of overactive bladder (OAB) in women.  The Minneapolis-based company said the first participant had been enrolled in a feasibility study evaluating physiological responses to therapy delivered with the FemPulse System. Observations from this feasibility study can further help elucidate the mechanisms of action and facilitate tailoring treatment plans for individual patients.  The clinical trial is an open-label, single-group assignment. Participants will wear a FemPulse device and will be monitored non-invasively during the activation of the device for up to six hours. The company anticipates data readout in the second half of 2019.  Fempulse System is neuromodulation platform, intended to provide mild electrical nerve stimulation to regulate bladder function and relieve the symptoms of OAB. The small, vaginal ring is disposable and may remain indwelling for days or weeks, affording discreet, personalized, continuous and self-managed therapy. In a release, Dr. Alexandra Haessler, CMO and Founder of FemPulse said, “Currently, there are limited convenient and effective treatment options for women suffering with OAB. The enrollment of our first participant in this study is an important milestone as we strive to provide a minimally invasive treatment that will improve the quality of life for women ...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Electronics Source Type: news